Servier Pharmaceuticals

• A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia

  Collaborator, Phase 2, Recruiting, 45 people, 6 Feb 2026

Sources: clinicaltrials.gov

• Dietary restriction reprograms CD8+ T cell fate to enhance anti-tumour immunity and immunotherapy responses

  Consulting or advice, 9 Dec 2025

• Primary age-related tauopathy

  Consulting or advice, 9 Oct 2025

Sources: pubmed.ncbi.nlm.nih.gov